Abstract & Overview
No abstract is available for this record.
Home/e-Resources/Medical Sciences/FDA approval of Zurzuvae (zuranolone) to combat postpartum depression
PeriodicalsMedical Sciences
FDA approval of Zurzuvae (zuranolone) to combat postpartum depression
Checking your access to this record.
Cite this record
Areeba Fareed, Rayyan Vaid (2023). FDA approval of Zurzuvae (zuranolone) to combat postpartum depression. Clinical Medicine Insights Psychiatry, 14. https://doi.org/10.1177/11795573231208983Copy in another style
Fareed, A., & Vaid, R. (2023). FDA approval of Zurzuvae (zuranolone) to combat postpartum depression. Clinical Medicine Insights Psychiatry, 14. https://doi.org/10.1177/11795573231208983
Author names are used as deposited, so check their order before you submit.
Metadata is harvested from open-access indexes and can be incomplete. Check a citation against the published version before relying on it — see our open access & attribution policy.
Related Literature
Immune cell involvement in brown adipose tissue functions
Alexandre Gallerand, Stoyan Ivanov
In Discovery Immunology
Reducción de la procrastinación académica mediante la Terapia de Aceptación y Compromiso: un estudio piloto
Lucía Toca Pérez, Miriam Alonso Fernández
In Clínica Contemporánea
The Clavien-Dindo Classification of Surgical Complications
Eduardo de Santibáñes, Claudio Bassi
In Annals of Surgery
Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients
John P. Stein, Stuart D. Boyd
In Journal of Clinical Oncology